Search results for " Adjuvant"

showing 10 items of 245 documents

Preclinical Retinal Neurodegeneration in a Model of Multiple Sclerosis

2012

Neurodegeneration plays a major role in multiple sclerosis (MS), in which it is thought to be the main determinant of permanent disability. However, the relationship between the immune response and the onset of neurodegeneration is still a matter of debate. Moreover, recent findings in MS patients raised the question of whether primary neurodegenerative changes can occur in the retina independent of optic nerve inflammation. Using a rat model of MS that frequently leads to optic neuritis, we have investigated the interconnection between neurodegenerative and inflammatory changes in the retina and the optic nerves with special focus on preclinical disease stages. We report that, before manif…

Retinal Ganglion CellsPathologyTime FactorsStilbamidinesgenetic structuresJournal ClubFreund's Adjuvantchemistry.chemical_compoundBlood-Retinal BarrierStudent’s SectionCell DeathMicrogliabiologyGeneral NeuroscienceRetinal DegenerationNeurodegenerationArticlesmedicine.anatomical_structureSpinal CordRetinal ganglion cellOptic nerveFemaleMicrogliaMyelin Proteinsmedicine.medical_specialtyMultiple SclerosisEnzyme-Linked Immunosorbent AssayRetinaMyelin oligodendrocyte glycoproteinMicroscopy Electron TransmissionAntigens CDOccludinGlial Fibrillary Acidic ProteinIn Situ Nick-End LabelingmedicineAnimalsOptic neuritisAquaporin 4Retinabusiness.industryMacrophagesMultiple sclerosisMembrane ProteinsRetinalOptic Nervemedicine.diseaseeye diseasesRatsDisease Models Animalchemistrybiology.proteinMyelin-Oligodendrocyte Glycoproteinsense organsbusinessNeuroscienceThe Journal of Neuroscience
researchProduct

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations : Results from a Multi-institutional European Retrospective Study

2022

[Purpose] The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9–mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association of dose and other clinicopathologic variables with survival was evaluated in a large multi-institutional European cohort.

STRUCTURAL BASISEXPRESSIONOncologyCancer Researchmedicine.medical_specialtyGastrointestinal Stromal Tumors3122 CancersMedizinAntineoplastic Agentsexon 9Adjuvants ImmunologicInternal medicinemedicineHumansFAILURERetrospective StudiesRISKRECEPTORGiSTProportional hazards modelbusiness.industryGASTROINTESTINAL STROMAL TUMORSHazard ratioImatinibRetrospective cohort studyExonsAdjuvant treatmentConfidence intervalGENOTYPEProto-Oncogene Proteins c-kitOncologyChemotherapy AdjuvantMutationPropensity score matchingCohortImatinib MesylateNeoplasm Recurrence LocalTYROSINE KINASE INHIBITORbusinessRare cancers Radboud Institute for Health Sciences [Radboudumc 9]medicine.drugGIST
researchProduct

Ne sous-estimons pas le risque à long terme de second cancer pulmonaire après exérèse chirurgicale d'un cancer du poumon non à petites cellules

2019

Etat de la question Plusieurs etudes ont montre que les survivants d’un cancer du poumon sont a haut risque de developper un second cancer broncho-pulmonaire (SCBP). L’evaluation du risque de SPBC au cours du temps a d’importante repercussion sur la strategie de surveillance post-chirurgicale des cancers du poumon non a petites cellules (CPNPC). L’objectif principal de cette etude etait de mesurer le risque de SCP sur le long terme en tenant compte du risque competitif de deces. Materiel et methodes Le risque cumule de SCBP a ete estime a l’aide de l’incidence cumulee chez des patients operes en resection complete d’un CPNPC de stade I a III diagnostiques entre 2002 et 2015 et recenses par …

Second cancer broncho-pulmonaireEpidemiologyPublic Health Environmental and Occupational HealthRadiothérapie adjuvantesuivi[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieEnquête en populationCancer du poumon non à petites-cellulesComputingMilieux_MISCELLANEOUSRisque compétitifs3. Good health
researchProduct

Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience

2014

Background: Optimally, secondary cytoreduction is acknowledged as a valid option in terms of oncologic outcome for patients with platinum-sensitive recurrent ovarian cancer. In cases of localized relapse, a laparoscopic approach has been attempted at various institutions, but studies on its role for this subset of patients still are limited. This report describes the authors' experience using laparoscopic secondary cytoreduction for patients with localized recurrent ovarian cancer. The results from a retrospective analysis of a prospective case series are reported. Methods: Between October 2011 and May 2013, 29 patients with localized recurrent ovarian cancer were selected for a laparoscopi…

Secondary cytoreductionmedicine.medical_treatmentTissue AdhesionsPostoperative ComplicationsLaparotomyLaparoscopyOvarian Neoplasmsmedicine.diagnostic_testMedicine (all)Middle Agedovarian cancerChemotherapy AdjuvantLymphatic MetastasisFemaleAdult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy; Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Laparoscopy; Laparotomy; Length of Stay; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Monitoring; Intraoperative; Neoplasm Recurrence; Local; Neoplasm Staging; Operative Time; Ovarian Neoplasms; Postoperative Complications; Retrospective Studies; Tissue AdhesionsAdultmedicine.medical_specialtyRecurrent ovarian cancer; Laparoscopy; Secondary cytoreductionOperative TimeAntineoplastic AgentsDisease-Free SurvivalLaparoscopicMonitoring IntraoperativeInternal medicineCarcinomamedicineHumansAgedNeoplasm StagingRetrospective StudiesLaparotomybusiness.industryGeneral surgeryCarcinomaRetrospective cohort studyLength of StayHepatologymedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIARecurrent Ovarian CancerLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalRecurrent ovarian cancerOvarian cancerbusinessFollow-Up StudiesAbdominal surgery
researchProduct

Sorafenib in advanced hepatocellular carcinoma

2008

none 25 BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Seconda…

SorafenibMaleNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularPyridinesPlaceboGastroenterologyDouble-Blind MethodInternal medicinemedicineCarcinomaHumansHEPATOCELLULAR CARCINOMAProtein Kinase InhibitorsAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryPhenylurea CompoundsHazard ratioBenzenesulfonatesLiver NeoplasmsGeneral MedicineTREATMENTMiddle AgedSorafenibmedicine.diseaseInterim analysisSurvival AnalysisRecurrent Hepatocellular Carcinomadigestive system diseasesSurgeryHEPATOCELLULAR CARCINOMA; SORAFENIB; TREATMENTChemotherapy AdjuvantHepatocellular carcinomaDisease ProgressionFemaleraf KinasesbusinessLiver cancermedicine.drug
researchProduct

Multimodal approaches to the treatment of hepatocellular carcinoma.

2008

The prevalence of hepatocellular carcinoma in Europe and the US is increasing and is currently the leading cause of death in patients with cirrhosis. Surveillance programs for patients with cirrhosis aim to detect tumors at an early stage, when the greatest therapeutic benefits can be achieved. Curative treatments for early-stage tumors include liver transplantation, resection and percutaneous ablation. Transarterial chemoembolization (TACE) and sorafenib can improve survival for patients with intermediate and advanced tumors, respectively. In clinical practice, combination therapies are often used, despite limited evidence to support this approach from randomized controlled trials. Combina…

SorafenibNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularCombination therapyWaiting ListsRadiofrequency ablationPyridinesmedicine.medical_treatmentSalvage therapyAntineoplastic AgentsLiver transplantationlaw.inventionInjectionslawPreoperative CaremedicineCombined Modality TherapyHumansChemoembolization TherapeuticSalvage TherapyHepatologyEthanolbusiness.industryepatocarcinoma cirrosi HBV HCVPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologySorafenibmedicine.diseaseCombined Modality TherapyEmbolization TherapeuticSurgeryLiver TransplantationHepatocellular carcinomaCatheter AblationRadiotherapy AdjuvantRadiologyPercutaneous ethanol injectionbusinessmedicine.drugNature clinical practice. Gastroenterologyhepatology
researchProduct

The Social and Economic Burden of Venous Leg Ulcers : Focus on the Role of Micronized Purified Flavonoid Fraction Adjuvant Therapy

2003

Ulcer HealingSystemic Adjuvant TherapyVenous UlcerChronic Venous InsufficiencyConventional TherapyAmerican Journal of Clinical Dermatology
researchProduct

Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer

2012

Objective: The aim of this study is to assess our results of treatment of women with stage I cervical cancer > 2 cm in diameter seeking fertility preservation. Treatment consisted of Laparoscopic Pelvic and Paraaortic Lymphadenectomy (LPPLND), and when no nodal metastasis was detected, neoadjuvant chemotherapy (NACT) followed by radical vaginal trachelectomy (RVT). Patients with positive lymph nodes underwent primary chemoradiation. Methods: A cohort of women younger than 40 years of age with stage I disease > 2 cm who underwent LPPLND and either NACT and RVT or chemoradiation. Oncological outcome was evaluated prospectively. Results: Eighteen women were eligible for this study. Twelve (67%…

Uterine Cervical NeoplasmRVTmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCervix UteriMetastasisParaaortic lymph nodesAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesFertility preservationProspective cohort studyLymph nodeNeoadjuvant therapyCervical cancerFertility PreservationObstetrics and GynecologyChemoradiotherapyNeoadjuvant Therapymedicine.anatomical_structureOncologyChemotherapy AdjuvantLymphatic MetastasisCarcinoma Squamous CellFemaleRadiologyHumanAdultmedicine.medical_specialtyPaclitaxelPelviRadical vaginal trachelectomyCervical carcinoma; Radical vaginal trachelectomy; Neoadjuvant chemotherapyAdenocarcinomaNeoadjuvant chemotherapyPelvisFollow-Up StudieHumansIfosfamideCervical carcinomaNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryGeneral surgeryLymphatic Metastasimedicine.diseaseProspective StudieLymph Node ExcisionLaparoscopyCisplatinNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

The Role of Self-Assembling Lipid Molecules in Vaccination

2018

Abstract The advent of vaccines represents one of the most significant advances in medical history. The protection provided by vaccines has greatly contributed in reducing the number of cases of infections and most notably to the eradication of small pox. A large number of new technologies and approaches in vaccine development are currently being investigated with the goal of providing the basis for the next generation of prophylactics against an ever-expanding list of emerging and reemerging pathogens. In this chapter, we will focus on the role of lipids and lipid self-assembling vesicles in new and promising vaccination approaches. We will start by describing how lipids can induce activat…

VaccinationInnate immune systemVaccine adjuvantmedicine.medical_treatmentHighly pathogenicSelf assemblingmedicineComputational biologyBiologyAdjuvant
researchProduct

Immunization of rainbow trout, Oncorhynchus mykiss (Walbaum), with a low molecular mass fraction isolated from Flavobacterium psychrophilum.

2008

Flavobacterium psychrophilum, the causative agent of rainbow trout fry syndrome has become a widespread fish pathogen in freshwater aquaculture worldwide. In this study, a low molecular mass fraction (P25-33), with an approximate weight of 25-33 kDa, was identified among F. psychrophilum strains in an immunoblotting analysis with anti-F. psychrophilum sera. The immunogenic efficacy of the isolated and extracted P25-33 was investigated in two intraperitoneal immunization trials with rainbow trout, Oncorhynchus mykiss (Walbaum). The first trial included immunizations using P25-33 with Freund's complete adjuvant (FCA) and the second trial included immunizations using P25-33, formalin-inactivat…

animal structuresanimal diseasesVeterinary (miscellaneous)medicine.medical_treatmentFreund's AdjuvantImmunoblottingFlavobacterium psychrophilumEnzyme-Linked Immunosorbent AssayAquatic ScienceBiologyFlavobacteriumMicrobiologyFish DiseasesImmune systemFlavobacteriaceae InfectionsmedicineAnimalsPathogenMolecular massAntibodies BacterialImmunizationOncorhynchus mykissBacterial Vaccinesbiology.proteinRainbow troutImmunizationAntibodyAdjuvantJournal of fish diseases
researchProduct